Why hormone therapy stops working after CDK4/6 — and what we do instead | Dr Dilanka De Silva
Who this is for This page is for people with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer whose cancer
Dr Dilanka De Silva
Should you really stay on hormone therapy longer? What the Breast Cancer Index (BCI) can tell you | Dr Dilanka De Silva
Who this is for This page is for people with hormone receptor–positive early breast cancer who are approaching five years
Mutation testing after CDK4/6 inhibitors: what should be checked next? | Dr Dilanka De Silva
Who this is for This page is for people with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer whose cancer
Why some early breast cancers now need more than hormone therapy alone (monarchE) | Dr Dilanka De Silva
Who this is for This page is for people with hormone receptor–positive, HER2-negative early breast cancer who have been told
Second opinion for advanced breast cancer in Melbourne: when should you consider one? | Dr Dilanka De Silva
Who this is for This page is for people with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer who are
CAPItello-281 (PTEN-deficient metastatic hormone-sensitive prostate cancer) capivasertib + abiraterone + ADT | Dr Dilanka De Silva
Who should read this? 1. Importance of early tumor testing (somatic) 2. People with newly diagnosed metastatic hormone-sensitive prostate cancer
Hormone therapy for prostate cancer. Agonists, antagonists, and choosing what fits | Dr Dilanka De Silva
Starting hormone therapy can feel overwhelming, especially when you are presented with different injection options and unfamiliar drug names. The
Hormone-sensitive vs hormone-resistant prostate cancer (what these words really mean) | Dr Dilanka De Silva
These words can sound frightening, but they are not a judgment on your future. “Hormone-sensitive” and “hormone-resistant” are simply ways
High-volume metastatic prostate cancer. What this term really means | Dr Dilanka De Silva
Who should read this? Anyone told they have “high-volume” or “high-burden” metastatic prostate cancer, especially if the label feels frightening
KEYNOTE-905 (EV-303) Peri-operative pembrolizumab + enfortumab vedotin in muscle-invasive bladder cancer | Dr Dilanka De Silva
Who should read this? People with muscle-invasive bladder cancer (MIBC) who are not eligible for cisplatin chemotherapy, or who have